IN8BIO Inc.
02/09/2026 | Press release | Distributed by Public on 02/09/2026 07:31
Management Change/Compensation (Form 8-K)
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On February 4, 2026, the Company's Board of Directors appointed Kate Rochlin, the Company's Chief Operating Officer, as President of the Company, effective February 4, 2026. Dr. Rochlin will continue to serve as the Company's Chief Operating Officer.
Biographical information about Dr. Rochlin can be found in the section of the Company's 2025 Proxy Statement, filed with the Securities and Exchange Commission on April 29, 2025, entitled "Executive Officers," which is incorporated by reference herein.
There is no family relationship between Dr. Rochlin and any other person that would require disclosure under Item 401(d) of Regulation S-K.Dr. Rochlin is also not a party to any transactions that would require disclosure under Item 404(a) of Regulation S-K.
IN8BIO Inc. published this content on February 09, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on February 09, 2026 at 13:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]